Viibryd (VI-brid) will be marketed as a new "dual-acting" serotonergic antidepressant

July 2011

Viibryd (VI-brid) will be marketed as a new "dual-acting" serotonergic antidepressant.

Viibryd (vilazodone) inhibits serotonin reuptake like SSRIs...plus it's also a partial serotonin agonist.

The company hoped Viibryd would be more effective than SSRIs.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscription Options

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Dyslipidemia Lots of patients are asking if they should stop taking niacin (Niaspan, etc) for dyslipidemia
Diabetes confusing the news about Avandia and Actos
Diabetes how to manage diabetes during fasting
Corticosteroids The methylprednisolone shortage is forcing questions about alternative corticosteroids
Thyroid Disorders Many older adults get too much levothyroxine (Synthroid, etc)
Antidepressants Viibryd (VI-brid) will be marketed as a new "dual-acting" serotonergic antidepressant
Antidepressants Is it okay to combine an SSRI (fluoxetine, etc) with an SNRI (Effexor, Cymbalta, or Savella)
Respiratory & Allergy Singulair is "as good as" inhaled corticosteroids or long-acting beta-agonists for asthma
Respiratory & Allergy Daliresp (DA-li-resp), a new oral tablet for severe COPD in patients with chronic bronchitis
Infectious Diseases the new oral drug Dificid (fidaxomicin) for Clostridium difficile diarrhea
Restless Legs new option for restless legs syndrome, Horizant (hor-i-zant)
Statins stronger dosing limits for simvastatin